Tag: pharmaceuticals
-
Novartis to Close U.K. Plant, Consolidate R&D Sites
The pharmaceutical company Novartis, headquartered in Basel, Switzerland, says it has begun talks to close its factory in Horsham, U.K. and consolidate its R&D facilities in Europe. According to the Financial Times, Novartis will continue its other U.K. plants in Grimsby, Liverpool, and Dundee. Closing the Horsham plant will mean the loss of 550 jobs,…
-
CDC Awards Grants to Reduce Health Care Infections
The U.S. Centers for Disease Control and Prevention (CDC) awarded $10 million for new research to five academic medical centers to develop and test new ways to reduce infections in health care settings. CDC estimates that 1 out of 20 hospitalized patients will acquire an infection, including drug-resistant infections, while receiving health care treatment for…
-
$4 Generics Could Save the U.S. $6 Billion
Researchers from University of Pittsburgh’s Graduate School of Public Health (GSPH) calculated the savings from using common discounted generic drug programs instead of full-priced generics or brand-name drugs. The team estimated those savings at nearly $6 billion. Their findings appear in the current issue of Archives of Internal Medicine (paid subscription required). The study covered…
-
U.K., Indian Spin Offs to Partner on Drug Discovery
InhibOx Ltd. in Oxford, U.K. and COSMIC Discoveries in Hyderabad, India, signed a partnership to offer drug discovery services combining their computational, medicinal, and synthetic chemistry capabilities. Both companies are spin-off enterprises of academic or research institutions — Oxford University and the Institute of Life Sciences, respectively. InhibOx provides computational drug discovery services, and has…
-
Wide Variations in Pain-Killers Prescribed by Family MDs
Some family physicians are prescribing opioids such as OxyContin at rates many times higher than their peers, according to a study by researchers at St. Michael’s Hospital and the Institute for Clinical Evaluative Sciences (ICES) in Toronto, Canada. The study, published online in the journal Canadian Family Physician, also showed an association between the number…
-
Report: Pharma Research Productivity Undercounted
In a new analysis, pharmaceutical market research company EvaluatePharma in London, U.K. says current methods of measuring productivity of the industry miss a big part of the industry’s output and thus give a misleading picture. The report suggests the pharma industry is in better shape than most observers indicate. EvaluatePharma says most industry watchers count…
-
Trial Shows Drug Improved Vision For Macular Edema Patients
A clinical trial of the drug Lucentis made by Genentech indicates patients with diabetic macular edema (DME) who received the drug had improved vision compared to patients who received a placebo. Genentech, a division of the Roche Group in South San Francisco, California, says vision improvements among those receiving Lucentis began to occur within seven…
-
Evotec to Partner with HHMI, Harvard on Diabetes Drugs
Evotec AG, a biotechnology company in Hamburg, Germany announced today a research collaboration with Harvard University in Cambridge, Massachusetts and Howard Hughes Medical Institute (HHMI), in Chevy Chase, Maryland to discover and develop new diabetes treatments. The partnership aims to identify and develop physiological mechanisms and targets that regulate beta cell replication. Beta cells are…
-
Nanoparticles Improve Delivery of Chemotherapy Drugs
An engineering professor at Northwestern University in Evanston, Illinois has discovered a process for combining nanoscale carbon particles to chemotherapy drugs to improve the drugs’ effectiveness on tumors. Dean Ho and his colleagues published their findings in this week’s issue of the journal Science Translational Medicine (paid subscription required). In studies of liver and breast…
-
Trial to Test Gene Therapy for Parkinson’s Disease
Rush University Medical Center in Chicago, Illinois and 10 other U.S. hospitals are testing a gene therapy called CERE-120 to evaluate if it can improve the symptoms of Parkinson’s disease. CERE-120 is an experimental gene transfer drug being developed by Ceregene Inc. in San Diego, California. The drug contains the human gene for neuturin, a…